Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.69 |
| ▸ | HTR6 | P50406 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703636 | 0.98 | HTR1A (0.69) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL8559095 | 0.98 | HTR1A (0.69) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL8554700 | 0.98 | HTR1A (0.69) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL8559799 | 0.98 | HTR1A (0.69) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL8559706 | 0.98 | HTR1A (0.69) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL8556091 | 0.97 | HTR1A (0.73) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL8556230 | 0.92 | GRM5 (0.66) | HTR1ADRD2HTR6MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27657032 | 0.90 | GRM5 (0.64) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL1703893 | 0.89 | MEN1 (0.67) | HTR1ADRD2HTR6MEN1KMT2A | |
| SCHEMBL14028451 | 0.88 | HTR1A (0.79) | HTR1ADRD2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989451-B2 | Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-08-02 | — | — | US | disclosed |
| US-7989451-B2 | Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-08-02 | — | — | US | disclosed |
| US-7989451-B2 | Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-08-02 | — | — | US | disclosed |
| US-20110071147-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | LUK KIN-CHUN | 2011-03-24 | — | — | US | disclosed |
| EP-1866292-B1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | AUCKLAND UNISERVICES LTD (NZ) | 2010-12-15 | — | — | EP | disclosed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | disclosed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | disclosed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | disclosed |
| WO-2009071577-A1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | WO | disclosed |
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
| EP-1917015-A1 | NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1778658-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | Siena Biotech S.p.A. (IT) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007019884-A1 | NOVEL 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006008133-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | SIENA BIOTECH S.P.A. (IT) | 2006-01-26 | — | — | WO | disclosed |
| US-20050256154-A1 | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | LUK KIN-CHUN | 2005-11-17 | — | — | US | disclosed |
| EP-0575954-B1 | Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process | MEDIOLANUM FARMACEUTICI SRL (IT) | 1998-09-02 | — | — | EP | disclosed |
| US-5424451-A | Used as cholinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1995-06-13 | — | — | US | disclosed |
| US-5302593-A | Aminoalkylcarbamic esters of eseroline suitable for use as chlorinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1994-04-12 | — | — | US | disclosed |
| EP-0575954-A1 | Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1993-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256154-A1 | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides | FGFR3, FGFR4, FGFR1 | HTR1A 2177/4885DRD2 3641/4885HTR6 1058/4885 |
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | CHRNA7, CHRNA5, CHRNA1 | HTR1A 108/4885DRD2 582/4885HTR6 192/4885 |
| US-20110071147-A1 | 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES | FGFR3, FGFR4, FGFR1 | HTR1A 2177/4885DRD2 3641/4885HTR6 1058/4885 |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | HIF1AN, HIF1A, HYOU1 | HTR1A 529/4885DRD2 1879/4885HTR6 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.